Structural and functional association of androgen receptor with telomeres in prostate cancer cells

Aging

Volumn 5, Issue 1, 2013, Pages 3-17

  Zhou, Junying ^a   Richardson, Michelle ^a   Reddy, Vidyavathi ^a   Menon, Mani ^a   Barrack, Evelyn ^a   Prem Veer Reddy, G ^a   Kim, Sahn Ho ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Androgen receptor; Casodex; DNA damage; Fragile telomeres; Genomic instability; Prostate cancer; Telomeres

Indexed keywords

EID: 84874986487     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100524     Document Type: Article

References (91)

1. Makarov VL, Hirose Y and Langmore JP. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell. 1997; 88:657-666.
2. de Lange T. How telomeres solve the end-protection problem. Science. 2009; 326:948-952.
3. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H and de Lange T. Mammalian telomeres end in a large duplex loop [see comments]. Cell. 1999; 97:503-514.
4. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005; 19:2100-2110.
5. Palm W and de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet. 2008; 42:301-334.
6. Celli GB and de Lange T. DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat Cell Biol. 2005; 7:712-718.
7. Else T, Trovato A, Kim AC, Wu Y, Ferguson DO, Kuick RD, Lucas PC and Hammer GD. Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis. Cancer Cell. 2009; 15:465-476.
8. Hockemeyer D, Daniels JP, Takai H and de Lange T. Recent expansion of the telomeric complex in rodents: Two distinct POT1 proteins protect mouse telomeres. Cell. 2006; 126:63-77.
9. Kim SH, Davalos AR, Heo SJ, Rodier F, Zou Y, Beausejour C, Kaminker P, Yannone SM and Campisi J. Telomere dysfunction and cell survival: roles for distinct TIN2-containing complexes. J Cell Biol. 2008; 181:447-460.
10. Sfeir A, Kosiyatrakul ST, Hockemeyer D, MacRae SL, Karlseder J, Schildkraut CL and de Lange T. Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell. 2009; 138:90-103.
11. Sfeir A, Kabir S, van Overbeek M, Celli GB and de Lange T. Loss of Rap1 induces telomere recombination in the absence of NHEJ or a DNA damage signal. Science. 2010; 327:1657-1661.
12. Wu L, Multani AS, He H, Cosme-Blanco W, Deng Y, Deng JM, Bachilo O, Pathak S, Tahara H, Bailey SM, Behringer RR and Chang S. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell. 2006; 126:49-62.
13. Bianchi A, Stansel RM, Fairall L, Griffith JD, Rhodes D and de Lange T. TRF1 binds a bipartite telomeric site with extreme spatial flexibility. Embo J. 1999; 18:5735-5744.
14. Bilaud T, Brun C, Ancelin K, Koering CE, Laroche T and Gilson E. Telomeric localization of TRF2, a novel human telobox protein. Nat Genet. 1997; 17:236-239.
15. Broccoli D, Chong L, Oelmann S, Fernald AA, Marziliano N, van Steensel B, Kipling D, Le Beau MM and de Lange T. Comparison of the human and mouse genes encoding the telomeric protein, TRF1: chromosomal localization, expression and conserved protein domains. Hum Mol Genet. 1997; 6:69-76.
16. Chong L, van Steensel B, Broccoli D, Erdjument-Bromage H, Hanish J, Tempst P and de Lange T. A human telomeric protein. Science. 1995; 270:1663-1667.
17. Hsu HL, Gilley D, Galande SA, Hande MP, Allen B, Kim SH, Li GC, Campisi J, Kohwi-Shigematsu T and Chen DJ. Ku acts in a unique way at the mammalian telomere to prevent end joining. Genes Dev. 2000; 14:2807-2812.
18. Lenain C, Bauwens S, Amiard S, Brunori M, Giraud-Panis MJ and Gilson E. The Apollo 5' exonuclease functions together with TRF2 to protect telomeres from DNA repair. Curr Biol. 2006; 16:1303-1310.
19. Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JH and de Lange T. ERCC1/XPF removes the 3' overhang from uncapped telomeres and represses formation of telomeric DNAcontaining double minute chromosomes. Mol Cell. 2003; 12:1489-1498.
20. Francia S, Weiss RS, Hande MP, Freire R and d'Adda di Fagagna F. Telomere and telomerase modulation by the mammalian Rad9/Rad1/Hus1 DNA-damage-checkpoint complex. Curr Biol. 2006; 16:1551-1558.
21. Zhu XD, Kuster B, Mann M, Petrini JH and Lange T. Cell-cycleregulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nat Genet. 2000; 25:347-352.
22. Badie S, Escandell JM, Bouwman P, Carlos AR, Thanasoula M, Gallardo MM, Suram A, Jaco I, Benitez J, Herbig U, Blasco MA, Jonkers J and Tarsounas M. BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping. Nat Struct Mol Biol. 2010; 17:1461-1469.
23. Min J, Choi ES, Hwang K, Kim J, Sampath S, Venkitaraman AR and Lee H. The breast cancer susceptibility gene BRCA2 is required for the maintenance of telomere homeostasis. J Biol Chem. 2012; 287:5091-5101.
24. Gu P, Min JN, Wang Y, Huang C, Peng T, Chai W and Chang S. CTC1 deletion results in defective telomere replication, leadingto catastrophic telomere loss and stem cell exhaustion. EMBO J. 2012; 31:2309-2321.
25. Deng Z, Dheekollu J, Broccoli D, Dutta A and Lieberman PM. The origin recognition complex localizes to telomere repeats and prevents telomere-circle formation. Curr Biol. 2007; 17:1989- 1995.
26. Opresko PL, von Kobbe C, Laine JP, Harrigan J, Hickson ID and Bohr VA. Telomere-binding protein TRF2 binds to and stimulates the Werner and Bloom syndrome helicases. J Biol Chem. 2002; 277:41110-41119.
27. Garcia-Cao M, O'Sullivan R, Peters AH, Jenuwein T and Blasco MA. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat Genet. 2004; 36:94-99.
28. Verdun RE and Karlseder J. The DNA damage machinery and homologous recombination pathway act consecutively to protect human telomeres. Cell. 2006; 127:709-720.
29. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L and DePinho RA. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature. 2000; 406:641-645.
30. Shay JW and Wright WE. Telomeres and telomerase: implications for cancer and aging. Radiat Res. 2001; 155:188- 193.
31. Gray JW and Collins C. Genome changes and gene expression in human solid tumors. Carcinogenesis. 2000; 21:443-452.
32. Shay JW and Wright WE. Role of telomeres and telomerase in cancer. Semin Cancer Biol. 2011; 21:349-353.
33. Cesare AJ and Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet. 2010; 11:319-330.
34. von Zglinicki T, Pilger R and Sitte N. Accumulation of singlestrand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic Biol Med. 2000; 28:64-74.
35. Smogorzewska A and de Lange T. Regulation of telomerase by telomeric proteins. Annu Rev Biochem. 2004; 73:177-208.
36. Martinez P, Thanasoula M, Munoz P, Liao C, Tejera A, McNees C, Flores JM, Fernandez-Capetillo O, Tarsounas M and Blasco MA. Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. Genes Dev. 2009; 23:2060-2075.
37. Konishi A and de Lange T. Cell cycle control of telomere protection and NHEJ revealed by a ts mutation in the DNAbinding domain of TRF2. Genes Dev. 2008; 22:1221-1230.
38. Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ and De Marzo AM. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res. 2002; 62:6405-6409.
39. Meeker AK. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol Oncol. 2006; 24:122-130.
40. Joshua AM, Shen E, Yoshimoto M, Marrano P, Zielenska M, Evans AJ, Van der Kwast T and Squire JA. Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. Prostate. 2011; 71:778-790.
41. Legrier ME, Guyader C, Ceraline J, Dutrillaux B, Oudard S, Poupon MF and Auger N. Hormone escape is associated with genomic instability in a human prostate cancer model. Int J Cancer. 2009; 124:1103-1111.
42. Ding Z, Wu CJ, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A, Chu GC, Wang G, Lu X, Labrot ES, Hu J, Wang W,Xiao Y, et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell. 2012; 148:896-907.
43. Kim SH, Han S, You YH, Chen DJ and Campisi J. The human telomere-associated protein TIN2 stimulates interactions between telomeric DNA tracts in vitro. EMBO Rep. 2003; 4:685- 691.
44. Kim SH, Richardson M, Chinnakannu K, Bai VU, Menon M, Barrack ER and Reddy GP. Androgen receptor interacts with telomeric proteins in prostate cancer cells. J Biol Chem. 2010; 285:10472-10476.
45. Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L and Aguirre J. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Prostate. 2007; 67:178-189.
46. Arnold JT, Liu X, Allen JD, Le H, McFann KK and Blackman MR. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate. 2007; 67:1152-1162.
47. Masiello D, Cheng S, Bubley GJ, Lu ML and Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 2002; 277:26321-26326.
48. Kolvenbag GJ, Blackledge GR and Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate. 1998; 34:61-72.
49. Zhan P, Lee EC, Packman K and Tenniswood M. Induction of invasive phenotype by Casodex in hormone-sensitive prostate cancer cells. J Steroid Biochem Mol Biol. 2002; 83:101-111.
50. Carroll AG, Voeller HJ, Sugars L and Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 1993; 23:123-134.
51. Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT and Roninson IB. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A. 1993; 90:3231-3235.
52. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO and Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990; 173:534-540.
53. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON and Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med. 1997; 3:402-408.
54. Reid P, Kantoff P and Oh W. Antiandrogens in prostate cancer. Invest New Drugs. 1999; 17:271-284.
55. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ and Balk SP. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res. 1997; 3:1383-1388.
56. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO and Mulder E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol. 1992; 41:665-669.
57. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324:787-790.
58. Prescott J, Jariwala U, Jia L, Cogan JP, Barski A, Pregizer S, Shen HC, Arasheben A, Neilson JJ, Frenkel B and Coetzee GA. Androgen receptor-mediated repression of novel target genes. Prostate. 2007; 67:1371-1383.
59. Agoulnik IU, Krause WC, Bingman WE, 3rd, Rahman HT, Amrikachi M, Ayala GE and Weigel NL. Repressors of androgen and progesterone receptor action. J Biol Chem. 2003; 278:31136-31148.
60. Mao Z, Seluanov A, Jiang Y and Gorbunova V. TRF2 is required for repair of nontelomeric DNA double-strand breaks by homologous recombination. Proc Natl Acad Sci U S A. 2007; 104:13068-13073.
61. Zhang P, Pazin MJ, Schwartz CM, Becker KG, Wersto RP, Dilley CM and Mattson MP. Nontelomeric TRF2-REST interaction modulates neuronal gene silencing and fate of tumor and stem cells. Curr Biol. 2008; 18:1489-1494.
62. Martinez P, Thanasoula M, Carlos AR, Gomez-Lopez G, Tejera AM, Schoeftner S, Dominguez O, Pisano DG, Tarsounas M and Blasco MA. Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites. Nat Cell Biol. 2010; 12:768-780.
63. Yang D, Xiong Y, Kim H, He Q, Li Y, Chen R and Songyang Z. Human telomeric proteins occupy selective interstitial sites. Cell Res. 2011; 21 1013-1027.
64. Dejardin J and Kingston RE. Purification of proteins associated with specific genomic Loci. Cell. 2009; 136:175-186.
65. Pisano S, Leoni D, Galati A, Rhodes D, Savino M and Cacchione S. The human telomeric protein hTRF1 induces telomere-specific nucleosome mobility. Nucleic Acids Res. 2010; 38:2247-2255.
66. Vannier JB, Pavicic-Kaltenbrunner V, Petalcorin MI, Ding H and Boulton SJ. RTEL1 dismantles T loops and counteracts telomeric G4-DNA to maintain telomere integrity. Cell. 2012; 149:795-806.
67. Arnoult N, Schluth-Bolard C, Letessier A, Drascovic I, Bouarich-Bourimi R, Campisi J, Kim SH, Boussouar A, Ottaviani A, Magdinier F, Gilson E and Londono-Vallejo A. Replication timing of human telomeres is chromosome arm-specific, influenced by subtelomeric structures and connected to nuclear localization. PLoS Genet. 2010; 6:e1000920.
68. O'Sullivan RJ and Karlseder J. Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol. 2010; 11:171-181.
69. Murnane JP. Telomere loss as a mechanism for chromosome instability in human cancer. Cancer Res. 2010; 70:4255-4259.
70. Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, Tanke HJ, Schroder FH and van Dekken H. Identification of genetic markers for prostatic cancer progression. Lab Invest. 2000; 80:931-942.
71. Heemers HV and Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007; 28:778-808.
72. Feldman BJ and Feldman D. The development of androgenindependent prostate cancer. Nat Rev Cancer. 2001; 1:34-45.
73. Pandini G, Mineo R, Frasca F, Roberts CT, Jr., Marcelli M, Vigneri R and Belfiore A. Androgens up-regulate the insulin-likegrowth factor-I receptor in prostate cancer cells. Cancer Res. 2005; 65:1849-1857.
74. Mayeur GL, Kung WJ, Martinez A, Izumiya C, Chen DJ and Kung HJ. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells. J Biol Chem. 2005; 280:10827-10833.
75. Murthy S and Reddy GP. Replitase: complete machinery for DNA synthesis. J Cell Physiol. 2006; 209:711-717.
76. D'Antonio JM, Vander Griend DJ and Isaacs JT. DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocr Relat Cancer. 2009; 16:325-332.
77. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK and Rosenfeld MG. Nuclear receptorinduced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell. 2009; 139:1069-1083.
78. Yunis JJ, Soreng AL and Bowe AE. Fragile sites are targets of diverse mutagens and carcinogens. Oncogene. 1987; 1:59-69.
79. Durkin SG and Glover TW. Chromosome fragile sites. Annu Rev Genet. 2007; 41:169-192.
80. Davis L and Maizels N. G4 DNA: at risk in the genome. EMBO J. 2011; 30:3878-3879.
81. Bosco N and de Lange T. A TRF1-controlled common fragile site containing interstitial telomeric sequences. Chromosoma. 2012.
82. Gilson E and Geli V. How telomeres are replicated. Nat Rev Mol Cell Biol. 2007; 8:825-838.
83. Takai H, Smogorzewska A and de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol. 2003; 13:1549-1556.
84. Kim SH, Beausejour C, Davalos AR, Kaminker P, Heo SJ and Campisi J. TIN2 mediates functions of TRF2 at human telomeres. J Biol Chem. 2004; 279:43799-43804.
85. Kim SH, Kaminker P and Campisi J. TIN2, a new regulator of telomere length in human cells [see comments]. Nat Genet. 1999; 23:405-412.
86. Bai VU, Cifuentes E, Menon M, Barrack ER and Reddy GP. Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase. J Cell Physiol. 2005; 204(2):381- 387.
87. Loayza D and De Lange T. POT1 as a terminal transducer of TRF1 telomere length control. Nature. 2003; 4241013-1018.
88. Morocho AM, Karamyshev V, Shcherbinina O and Polushin N. Biotin-labeled oligonucleotides with extraordinarily long tethering arms. Methods Mol Biol. 2005; 288:225-240
89. Hultdin M, Gronlund E, Norrback K, Eriksson-Lindstrom E, Just T and Roos G. Telomere analysis by fluorescence in situ hybridization and flow cytometry. Nucleic Acids Res. 1998; 26(16):3651-3656.
90. Bailey SM, Meyne J, Chen DJ, Kurimasa A, Li GC, Lehnert BE and Goodwin EH. DNA double-strand break repair proteins are required to cap the ends of mammalian chromosomes. Proc Natl Acad Sci U S A. 1999; 96:14899-14904.
91. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW and Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgenregulated activity of the prostate-specific antigen promoter. Mol Endocrinol. 1997; 11:148-161.